Roger Stock Price, News & Analysis

Genentech, part of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced the discontinuation of dosing in the Phase III GENERATION HD1 study of tominersen for Huntington’s disease based on data reviewed by an Independent Data Monitoring Committee. While no new safety signals were identified, the study’s potential benefit/risk profile led to this decision. The open-label extension study (GEN-EXTEND) will also pause dosing for further analysis. Genentech aims to continue following participants for safety and outcomes, sharing insights within the HD community once full data is analyzed.

Genentech, part of Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced that the Phase III IMpower010 study of Tecentriq^® (atezolizumab) met its primary endpoint of disease-free survival (DFS) in non-small cell lung cancer (NSCLC) patients at interim analysis. Significant DFS improvement was observed, especially in PD-L1-positive patients. Follow-up analyses will assess overall survival data. Tecentriq's safety profile remained consistent. Data will be presented at medical meetings and submitted to regulatory authorities for further evaluation.

Genentech, part of Roche Group (SIX: RO, ROG; OTCQX: RHHBY), released promising 2-year results from the SUNFISH study on Evrysdi™ (risdiplam) for Type 2 and non-ambulant Type 3 spinal muscular atrophy (SMA) in patients aged 2-25. Improvements in motor function achieved at 12 months were maintained or enhanced at 24 months across primary and secondary endpoints. The study, presented at the 2021 MDA Conference, showed no new safety signals. The findings reinforce Evrysdi's potential long-term benefits and favorable risk profile for SMA patients.

Genentech announced that the global Phase III REMDACTA study of Actemra (tocilizumab) plus Veklury (remdesivir) for treating severe COVID-19 pneumonia did not meet its primary endpoint of improved hospital discharge time. No new safety signals were reported for Actemra. The study, conducted with Gilead Sciences, failed to meet key secondary endpoints as well. Previous studies COVACTA did not meet its primary endpoint, while EMPACTA did. Genentech remains committed to evaluating the overall data for potential application of Actemra in COVID-19 treatments.

Genentech has announced the voluntary withdrawal of Tecentriq® (atezolizumab) from the U.S. market for prior-platinum treated metastatic urothelial carcinoma (mUC), following FDA consultation. This decision follows the failure of the IMvigor211 study to meet its primary overall survival endpoint. Genentech emphasizes that other approved indications for Tecentriq remain unaffected. The withdrawal reflects the evolving treatment landscape and aims to uphold the integrity of the FDA's Accelerated Approval Program.

Genentech announced FDA approval for Actemra® (tocilizumab) subcutaneous injection to slow pulmonary function decline in adults with systemic sclerosis-associated interstitial lung disease (SSc-ILD). This marks the first biologic therapy approved for this condition, impacting approximately 75,000 patients in the U.S. Key findings from the focuSSced Phase III trial indicated that Actemra reduced lung function decline compared to placebo, although the primary endpoint related to skin fibrosis was not met.

Common side effects included infections, aligning with Actemra's known safety profile.

Rogers Corporation (NYSE:ROG) has released its inaugural 2021 ESG Report, detailing its environmental, social, and governance strategies. President and CEO Bruce D. Hoechner emphasized the company's commitment to responsible corporate citizenship and sustainability, tracing roots back to the founder's initiatives on recycling. The report adheres to prominent sustainability frameworks and covers topics such as carbon footprint, diversity, and COVID-19 response. It showcases Rogers' contributions to electric vehicles, renewable energy, and medical applications, aiming for a cleaner and safer future.

Genentech, part of the Roche Group, announced publication of Evrysdi™ (risdiplam) data from the pivotal FIREFISH study. The study showed that 90% of infants with symptomatic Type 1 spinal muscular atrophy (SMA) survived without permanent ventilation after 12 months of treatment. Additionally, 33% of infants could sit independently for at least 5 seconds. The data highlights the drug's effectiveness in increasing survival of motor neuron (SMN) protein levels. Evrysdi, FDA-approved in August 2020, has promising implications for treating SMA in infants.

Rogers Corporation (NYSE:ROG) reported Q4 2020 net sales of $210.7 million, marking a 4% increase from Q3 and a 21% rise year-on-year. Gross margin improved to 38.3%, driven by operational efficiencies despite rising costs. For the full year, net sales totaled $802.6 million, a decline of 11% due to pandemic-related challenges. GAAP earnings per diluted share were $0.81 in Q4, up from $0.37 in Q3, while full-year earnings rose to $2.67. The company anticipates Q1 2021 net sales between $215-$225 million, amidst recovery from a facility fire in South Korea.